SG10201405940VA - Expression system - Google Patents

Expression system

Info

Publication number
SG10201405940VA
SG10201405940VA SG10201405940VA SG10201405940VA SG10201405940VA SG 10201405940V A SG10201405940V A SG 10201405940VA SG 10201405940V A SG10201405940V A SG 10201405940VA SG 10201405940V A SG10201405940V A SG 10201405940VA SG 10201405940V A SG10201405940V A SG 10201405940VA
Authority
SG
Singapore
Prior art keywords
expression system
expression
Prior art date
Application number
SG10201405940VA
Inventor
Blais Normand
Marc Helene Dehottay Philippe
Dewerchin Marianne
Goffin Philippe
Martin Denis
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41402733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201405940V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of SG10201405940VA publication Critical patent/SG10201405940VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1077Pentosyltransferases (2.4.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/02Pentosyltransferases (2.4.2)
    • C12Y204/02036NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201405940VA 2009-10-08 2010-10-07 Expression system SG10201405940VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0917647.0A GB0917647D0 (en) 2009-10-08 2009-10-08 Expression system

Publications (1)

Publication Number Publication Date
SG10201405940VA true SG10201405940VA (en) 2014-11-27

Family

ID=41402733

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201405940VA SG10201405940VA (en) 2009-10-08 2010-10-07 Expression system

Country Status (17)

Country Link
US (4) US9422345B2 (en)
EP (3) EP2486047B1 (en)
JP (3) JP2013507113A (en)
KR (1) KR20120099672A (en)
CN (1) CN102639558B (en)
AR (1) AR078533A1 (en)
AU (1) AU2010305342B2 (en)
BR (1) BR112012007984B1 (en)
CA (1) CA2776969C (en)
EA (1) EA201290134A1 (en)
ES (3) ES2750023T3 (en)
GB (1) GB0917647D0 (en)
IL (1) IL218930A0 (en)
MX (2) MX2012004092A (en)
SG (1) SG10201405940VA (en)
UY (1) UY32933A (en)
WO (1) WO2011042516A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
GB0917647D0 (en) * 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
EP2553102B1 (en) * 2010-03-30 2015-12-09 Pfenex Inc. High level expression of recombinant toxin proteins
RU2580620C2 (en) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи STABLE COMPOSITIONS OF ANTIGENS Neisseria meningitidis rLP2086
PE20140173A1 (en) 2010-09-10 2014-02-20 Wyeth Llc NON-LIPIDED VARIANTS OF NEISSERIA MENINGITIDIS ANTIGENS ORF2086
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
ES2750525T3 (en) * 2012-12-27 2020-03-26 Glaxosmithkline Biologicals Sa Procedures and compositions related to CRM197
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
MX369534B (en) 2013-09-08 2019-11-11 Pfizer Neisseria meningitidis compositions and methods thereof.
US11060123B2 (en) 2014-01-31 2021-07-13 Fina Biosolutions, Llc Production of soluble recombinant protein without n-terminal methionine
WO2015117093A1 (en) 2014-01-31 2015-08-06 Fina Biosolutions, Llc Expression and purification of crm197 and related proteins
WO2015134402A1 (en) * 2014-03-03 2015-09-11 Scarab Genomics, Llc Enhanced production of recombinant crm197 in e. coli
CA2941687A1 (en) 2014-03-14 2015-09-17 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
CN107109416A (en) 2014-11-20 2017-08-29 生物E有限公司 For CRM197High level expression codon optimised polynucleotide
CN107249626A (en) 2015-02-19 2017-10-13 辉瑞大药厂 Neisseria meningitidis composition and its method
MA47223A (en) 2016-12-30 2019-11-06 Sutrovax Inc POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
KR101908590B1 (en) * 2017-02-01 2018-10-16 (주)포바이오코리아 Expression and purification method of soluble crm197 proteins
EP3444269A1 (en) * 2017-08-17 2019-02-20 National Research Council of Canada Systems and methods for the production of diphtheria toxin polypeptides
US20200331973A1 (en) * 2017-09-01 2020-10-22 Lorven Biologics Private Limited Nucleic acid encoding crm197 and process for improved expression thereof
EP3679050B1 (en) * 2017-09-05 2023-11-22 Scarab Genomics, LLC Methods and compositions for improved expression of recombinant proteins
AU2018354069A1 (en) 2017-10-27 2020-06-11 Pelican Technology Holdings, Inc. Bacterial leader sequences for periplasmic protein expression
WO2019083793A1 (en) 2017-10-27 2019-05-02 Pfenex Inc. Method for production of recombinant erwinia asparaginase
SG11202005255PA (en) 2017-12-06 2020-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
KR102059619B1 (en) 2018-04-17 2019-12-26 강원대학교산학협력단 Mutant strain for simultaneously fermentescible of glucose and xylose mixed sugars
WO2020033398A1 (en) * 2018-08-06 2020-02-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating atii cell-dependent lung diseases
TWI788610B (en) 2018-12-19 2023-01-01 美商默沙東有限責任公司 Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2020243460A1 (en) 2019-03-18 2021-10-07 Bio-Rad Abd Serotec Gmbh Protection of SpyTag-containing periplasmic fusion proteins from protease Tsp and ompT degradation
KR102099342B1 (en) * 2019-09-03 2020-04-10 주식회사 제노포커스 Expression Method of CRM197 Protein
BE1029145B1 (en) 2021-02-26 2022-09-27 Curavac Europe METHOD FOR PRODUCING A PERIPLASMIC FORM OF THE PROTEIN CRM197

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
JPS62158491A (en) * 1985-12-28 1987-07-14 Wakunaga Pharmaceut Co Ltd Production of purified protein
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
EP0460021A4 (en) * 1989-02-23 1992-08-26 Seragen, Inc. Chimeric toxin
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
DE69231306T2 (en) * 1991-02-26 2001-01-11 Zeneca Ltd Fermentation process for the production of peptides by a host
NZ249704A (en) 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
WO1993021769A1 (en) 1992-05-06 1993-11-11 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
ES2118963T3 (en) 1992-05-23 1998-10-01 Smithkline Beecham Biolog COMBINED VACCINES, CONTAINING HEPATITIS B SURFACE ANTIGEN AND OTHER ANTIGENS.
DE69327534T2 (en) 1992-06-18 2000-06-08 Harvard College VACCINE AGAINST DIPHTHERIETOXIN
KR100376361B1 (en) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 How to activate soluble carbohydrates using new cyanating reagents for the production of immunogenic constructs
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
ATE241384T1 (en) 1995-03-22 2003-06-15 Jackson H M Found Military Med PREPARATION OF IMMUNOGENIC CONSTRUCTS USING SOLUBLE CARBOHYDRATES ACTIVATED BY ORGANIC CYANYLATION REAGENTS
CN1146444C (en) 1995-06-23 2004-04-21 史密斯克莱·比奇曼生物公司 Vaccine composition comprising polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
KR100401423B1 (en) 2001-01-10 2003-10-17 주식회사 엘지생명과학 A Manufacturing Method of Combined Vaccine
WO2005076010A2 (en) * 2004-02-06 2005-08-18 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
NZ564695A (en) * 2005-07-08 2009-02-28 Univ Zuerich Phage display using cotranslational translocation of fusion polypeptides
GB0917647D0 (en) * 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system

Also Published As

Publication number Publication date
US20120289688A1 (en) 2012-11-15
US20180258146A1 (en) 2018-09-13
EP2486047A2 (en) 2012-08-15
BR112012007984A2 (en) 2016-11-22
BR112012007984B1 (en) 2021-11-03
AR078533A1 (en) 2011-11-16
KR20120099672A (en) 2012-09-11
ES2750023T3 (en) 2020-03-24
EP3170837A2 (en) 2017-05-24
WO2011042516A3 (en) 2011-06-16
JP2018085994A (en) 2018-06-07
CN102639558B (en) 2015-11-25
IL218930A0 (en) 2012-07-31
CN102639558A (en) 2012-08-15
MX2012004092A (en) 2012-04-20
US9422345B2 (en) 2016-08-23
AU2010305342B2 (en) 2016-05-26
ES2969888T3 (en) 2024-05-23
US20190322708A1 (en) 2019-10-24
JP2017029155A (en) 2017-02-09
EP3480209A3 (en) 2019-06-19
JP6636546B2 (en) 2020-01-29
UY32933A (en) 2011-05-31
US20170137475A1 (en) 2017-05-18
JP2013507113A (en) 2013-03-04
AU2010305342A1 (en) 2012-05-03
EA201290134A1 (en) 2012-10-30
MX347256B (en) 2017-04-20
CA2776969A1 (en) 2011-04-14
EP3170837B1 (en) 2019-08-21
EP3170837A3 (en) 2017-07-19
US9994622B2 (en) 2018-06-12
ES2609066T3 (en) 2017-04-18
EP3480209A2 (en) 2019-05-08
WO2011042516A2 (en) 2011-04-14
GB0917647D0 (en) 2009-11-25
CA2776969C (en) 2019-01-15
JP6305478B2 (en) 2018-04-04
EP3480209B1 (en) 2023-11-29
EP2486047B1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
IL218930A0 (en) Expression system
HUP0900538A2 (en) Laparo-endoscope system
EP2314957A4 (en) Multi-evaporation system
HK1152266A1 (en) Component system
GB0904414D0 (en) Keystep system
GB2476784B (en) Anti-scour system
ZA201006863B (en) Positioning system
EP2391894A4 (en) Relative time system
PL2478323T3 (en) Multi-weapons system
EP2396498A4 (en) Autochoke system
GB0914323D0 (en) Retention system
GB2468594B (en) Image-to-speech system
GB0914700D0 (en) Location system
GB201016969D0 (en) Expression system
PL2464943T3 (en) System integration
GB2473957B (en) Positioning system
GB0905967D0 (en) System
GB0904707D0 (en) System
GB2474011B (en) Attachment system
GB0900319D0 (en) Hydrocharger
EG26908A (en) Waterproofing-drainage system
GB201008258D0 (en) Gamex system
GB0902303D0 (en) ieducate system
GB0920713D0 (en) Savyor system
GB0920531D0 (en) Tidysqueeze system